Crescent Biopharma, Inc. (CBIO) Stock Forecast
CBIO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.88 / 5 from 8 analysts
- Price target
- $31.50 average of analyst targets
- Upside to target
- +166.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.72
- 52-week range
- $8.94 – $26.98
CBIO analyst ratings
8 analystsNumber of analysts at each rating.
CBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.57 | −$0.62 | −$0.53 | −$1.37 | +58.3% | 3 |
| Current fiscal year (2026) | −$2.35 | −$2.36 | −$2.35 | −$12.81 | +81.6% | 3 |
| Next fiscal year (2027) | −$2.63 | −$3.27 | −$1.98 | −$2.35 | −11.8% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $357,140 | $0 | $2.5M | 0.0% | 7 |
| Current fiscal year (2026) | $1.7M | $1.0M | $6.0M | 0.0% | 7 |
| Next fiscal year (2027) | $4.8M | $0 | $22.5M | +177.4% | 7 |
CBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CBIO revenue: reported and forecast
CBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.66 | −$0.66 | −$0.66 | −$0.61 | −$0.57 | −14.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.62 | −$2.62 | −$2.62 | −$2.49 | −$2.35 | −10.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.94 | −$2.94 | −$2.94 | −$2.98 | −$2.63 | −10.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CBIO beat in 8 of 12.
What analysts expect from CBIO
8 analysts cover Crescent Biopharma; their consensus rating is strong buy (4.88 on a 1–5 scale, where 5 is a strong buy). The average price target is $31.50, 166.0% above the latest close of $11.84. Analysts expect earnings of −$2.35 per share for 2026, +81.6% from a year earlier. For 2027 the average estimate is −$2.63 per share on revenue of $4.8 million. Crescent Biopharma beat the EPS estimate in 8 of the last 12 quarters.
Related: CBIO income statement, CBIO key metrics, CBIO chart. See the CBIO stock overview for the latest quote and news.
CBIO forecast FAQ
What is Crescent Biopharma's price target?
The average analyst price target for Crescent Biopharma is $31.50, 166.0% above the latest close of $11.84.
Is Crescent Biopharma a buy, hold or sell?
Of 8 analysts covering Crescent Biopharma, 7 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Crescent Biopharma's EPS forecast?
Analysts forecast −$2.35 per share for 2026 (range −$2.36 to −$2.35); for 2027 the estimate is −$2.63.
What is Crescent Biopharma's revenue forecast?
The average revenue estimate for 2026 is $1.7 million, growth of 0.0%; for 2027 it is $4.8 million.
When does Crescent Biopharma report earnings?
Crescent Biopharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.72.
Does Crescent Biopharma usually beat earnings estimates?
Crescent Biopharma reported EPS at or above the analyst estimate in 8 of the last 12 quarters.